Contribution: Industrial Research Assistance Program – Contributions to Firms
Qu Biologics Inc.
$2,780,109.00
COVID-19 Rapid Response: Preclinical studies for safety and efficacy of lung-directed Site-Specific Immunomodulator (SSI) in COVID-19 relevant animal model
FY 2020-21 · 2020-12-01
Summary
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
842333817
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-12-01 | 2020-21 | $109,764.00 |
| 2 | 2020-12-01 | 2020-21 | $229,764.00 |
| 3 | 2020-12-01 | 2020-21 | $2,200,959.00 |
| 4 | 2020-12-01 | 2020-21 | $2,200,959.00 |
| 5 | 2020-12-01 | 2020-21 | $2,200,959.00 |
| 6 | 2020-12-01 | 2020-21 | $2,940,481.00 |
| 7 | 2020-12-01 | 2020-21 | $2,780,109.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -160,372 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de - 160 372 dollars.
Agreement End Date
2022-08-31
Agreement Number
961167
Agreement Start Date
2020-12-01
Agreement Title
COVID-19 Rapid Response: Preclinical studies for safety and efficacy of lung-directed Site-Specific Immunomodulator (SSI) in COVID-19 relevant animal model
Agreement Title (French)
Réponse rapide face à la COVID-19 : Études précliniques sur la sécurité et l'efficacité de l'immunomodulateur spécifique au site (ISS) dirigé vers les poumons dans le modèle animal pertinent pour la COVID-19
Agreement Type
Contribution
Agreement Value
$2,780,109.00
Amendment Date
2022-08-30
Amendment Number
7
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
Description (French)
Ce projet fournira des preuves de validation de principe de la sécurité et de l'efficacité de l'utilisation prophylactique et thérapeutique d'un immunomodulateur dirigé vers les poumons, et ce, afin de prévenir une infection grave par la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby South
Federal Riding (French)
Burnaby-Sud
Federal Riding Number
59003
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
842333817
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
Qu Biologics Inc.
Recipient Postal Code
V5G 4X4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q3-961167
